MONTREAL, QUEBEC -- (MARKET WIRE) -- November 21, 2006 -- ART Advanced Research Technologies Inc. (“ART”) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce that it has entered into agreements to repurchase all of its outstanding senior secured convertible debentures (the “Debentures”). The Debentures were issued on July 28, 2005 to a limited number of U.S. institutional investors. The aggregate purchase price will consist of the outstanding principal amount of the Debentures currently outstanding (US$2,500,000), plus a premium of 15% on such outstanding principal amount, plus accrued and unpaid interest thereon, for a total of US$2,913,623.
